Elisabet de Los Pinos - 28 Oct 2021 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role: Chief Executive Officer, Director
Signature: /s/ Julie Feder
Issuer symbol: AURA
Transactions as of: 28 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 28 Oct 2021, 20:30:12 UTC
Next filing: 02 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AURA	Common Stock						126,860	28 Oct 2021	By: EdIP Revocable Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	3,649	$5.48	Direct	F2
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	5,474	$5.75	Direct	F2
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	10,948	$5.07	Direct	F2
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	14,598	$5.48	Direct	F2
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	14,598	$5.21	Direct	F2
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	364,963	$2.74	Direct	F3
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	63,548	$3.15	Direct	F4
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	194,889	$4.25	Direct	F5
holding	AURA	Stock Option (Right to Buy)							28 Oct 2021	Common Stock	620,437	$5.48	Direct	F6
holding	AURA	Series A-1 Preferred Stock							28 Oct 2021	Common Stock	3,042		By: EdIP Revocable Trust	F1, F7, F8
holding	AURA	Series A-2 Preferred Stock							28 Oct 2021	Common Stock	1,510		By: EdIP Revocable Trust	F1, F9, F10

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.
F2	This option is fully vested.
F3	The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 21, 2018.
F4	The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2019
F5	The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2020.
F6	The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021.
F7	Immediately prior to the completion of the Issuer's initial public offering, each share of Series A-1 Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for-one basis and has no expiration date.
F8	Upon the closing of the Issuer's initial public offering, all shares of Series A-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.
F9	Immediately prior to the completion of the Issuer's initial public offering, each share of Series A-2 Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for-one basis and has no expiration date.
F10	Upon the closing of the Issuer's initial public offering, all shares of Series A-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3.